Abstract:Background: With new randomised pieces of evidence and the latest clinical practice guideline from the BMJ emerging in 2018, an updated analysis of best available evidence on the controversial effects of corticosteroids in sepsis is warranted. Objectives: To comprehensively evaluate whether corticosteroids are beneficial in reducing mortality and what cumulative dosage, daily dosage, and duration of corticosteroid treatment would enable adult patients with sepsis to reach the critical point of benefits. Methods: Ovid MEDLINE, Ovid EMbase, Cochrane Library, and LILACS database were searched until March 22, 2019. Results: Thirty RCTs with 8,836 participants were identified. Long course low-dose corticosteroid therapy could improve 28-day mortality (RR = 0.90, 95% CI = 0.84–0.97; high quality), intensive care unit mortality (RR = 0.87; 95% CI = 0.79–0.95; moderate quality), and in-hospital mortality (RR = 0.88, 95% CI = 0.79–0.997; high quality). However, we found no benefits for 90-day, 180-day, and 1-year mortality. Subgroup results of long course corticosteroid treatment in a population with septic shock and vasopressor-dependent septic shock, corticosteroid regimen with hydrocortisone plus fludrocortisone, corticosteroid dosing strategies including bolus dosing and infusion dosing, the strategies of abrupt discontinuation, timing of randomisation ≤24 h, impact factor of ≥10, and sample size ≥500 were associated with a marginally reduction in 28-day mortality. Conclusions: This meta-analysis found that the long course low-dose and not short course high-dose corticosteroid treatment could marginally improve short-term 28-day mortality with high quality, especially septic shock and vasopressor-dependent septic shock, and it is recommended that long course (about 7 days) low-dose (about 200–300mg per day) hydrocortisone (or equivalent) with cumulative dose (at least about 1,000mg) may be a viable management option for overall patients with sepsis, and it can be also adapted to patient with septic shock alone. Early hydrocortisone plus fludrocortisone administration, via continuous infusion or bolus dosing, is also particularly important for the prognosis. Abrupt discontinuation of corticosteroids, as opposed to the conventional tapered discontinuation, may be considered as a desirable option in 28-day mortality. The safety profile of long course low-dose corticosteroid treatment, including adverse hyperglycaemia and hypernatraemia events, remains a concern, although these events could be easily treated. Clinical Trial Registration: PROSPERO, identifier CRD 42018092849.

Association Between Short-Term Systemic Use of Glucocorticoids and Prognosis of Cardiogenic Shock: a Retrospective Analysis

Efficacy and safety of corticosteroids for septic shock in immunocompromised patients: A cohort study from MIMIC

Effects and Safety of Separate Low-Dose Hydrocortisone Use in Patients with Septic Shock: A Meta-Analysis

Corticosteroid in Non-Covid-19 Induced Community-Acquired Pneumonia, a Meta-Analysis.

Effects of the working experience, educational background, professional titles, and hospital grades of intensive care unit doctors on clinical glucocorticoid use in acute respiratory distress syndrome

Association between glucocorticoid use and all-cause mortality in critically ill patients with heart failure: A cohort study based on the MIMIC-III database

Corticosteroid Administration is Associated with Improved Outcome of Patients Presenting High Inflammatory Cytokine Levels During Septic Shock

Association of Corticosteroid Treatment with Outcomes in Adult Patients with Sepsis: A Systematic Review and Meta-analysis.

Association between glucocorticoid administration and outcomes in patients with ARDS based on the MIMIC-III database

The Timing of Initiating Hydrocortisone and Long-term Mortality in Septic Shock

[A Meta-Analysis to Evaluate the Effects of Corticosteroids on the Outcomes of Patients with Septic Shock].

Clinical Utilization of Stress Dose Hydrocortisone in Adult Patients with Septic Shock: A Retrospective Observational Study at a Large Academic Medical Center

Efficacy and prognosis of glucocorticoid therapy for septic shock: a meta analysis

Impact and Beneficial Critical Points of Clinical Outcome in Corticosteroid Management of Adult Patients with Sepsis: Meta-Analysis and GRADE Assessment

Association of systemic corticosteroid use with prognosis of patients with acute exacerbations of chronic obstructive pulmonary disease in the intensive care unit: a propensity score-matched cohort study

Corticosteroid Therapy in Critically Ill Patients with COVID-19: a Multicenter, Retrospective Study

Meta-Analysis: The Effect of Steroids on Survival and Shock during Sepsis Depends on the Dose

Adverse Outcomes Associated With Corticosteroid Use in Critical COVID-19: A Retrospective Multicenter Cohort Study

Stress hyperglycemia is associated with poor prognosis in critically ill patients with cardiogenic shock

Aetiology and prognostic risk factors of mortality in patients with pneumonia receiving glucocorticoids alone or glucocorticoids and other immunosuppressants: a retrospective cohort study

[Impact of systemic corticosteroids on the clinical outcomes in patients with severe community-acquired pneumonia: a multi-center retrospective study].